GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » Cyclically Adjusted PB Ratio

Tenax Therapeutics (Tenax Therapeutics) Cyclically Adjusted PB Ratio : 0.00 (As of May. 23, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-23), Tenax Therapeutics's current share price is $3.56. Tenax Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $28,521.90. Tenax Therapeutics's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Tenax Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Tenax Therapeutics's highest Cyclically Adjusted PB Ratio was 18.90. The lowest was 0.01. And the median was 0.15.

TENX's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.74
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Tenax Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $6.348. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $28,521.90 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Tenax Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Tenax Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Cyclically Adjusted PB Ratio Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.08 0.05 0.01 -

Tenax Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tenax Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Tenax Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenax Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's Cyclically Adjusted PB Ratio falls into.



Tenax Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Tenax Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.56/28521.9
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenax Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Tenax Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.348/131.7762*131.7762
=6.348

Current CPI (Mar. 2024) = 131.7762.

Tenax Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201404 95,270.115 100.023 125,514.218
201407 92,655.682 100.520 121,466.269
201410 88,167.045 100.176 115,979.637
201501 85,640.909 98.604 114,452.667
201504 80,032.955 99.824 105,650.755
201507 76,560.227 100.691 100,196.103
201510 72,647.727 100.346 95,401.942
201603 62,878.409 100.470 82,470.835
201606 57,834.091 101.688 74,946.397
201609 53,060.227 101.861 68,643.299
201612 19,478.409 101.863 25,198.534
201703 16,037.500 102.862 20,545.553
201706 12,802.273 103.349 16,323.653
201709 11,550.000 104.136 14,615.704
201712 10,093.182 104.011 12,787.493
201803 8,792.308 105.290 11,004.107
201806 6,849.451 106.317 8,489.671
201809 5,367.391 106.507 6,640.844
201812 4,967.089 105.998 6,175.067
201903 2,685.714 107.251 3,299.874
201906 2,067.146 108.070 2,520.606
201909 1,552.732 108.329 1,888.805
201912 895.962 108.420 1,088.972
202003 683.800 108.902 827.432
202006 480.032 108.767 581.579
202009 938.403 109.815 1,126.069
202012 586.312 109.897 703.041
202103 330.769 111.754 390.029
202106 93.397 114.631 107.366
202109 459.619 115.734 523.327
202112 269.524 117.630 301.938
202203 101.968 121.301 110.774
202206 430.730 125.017 454.019
202209 210.993 125.227 222.029
202212 52.112 125.222 54.840
202303 52.450 127.348 54.274
202306 44.327 128.729 45.376
202309 37.840 129.860 38.399
202312 27.149 129.419 27.643
202403 6.348 131.776 6.348

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Tenax Therapeutics  (NAS:TENX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Tenax Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics (Tenax Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Executives
Robyn Hunter director 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano director, officer: CEO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich officer: Chief Medical Officer C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck director 2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl director
James P. Mitchum director C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley officer: Chief Executive Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502

Tenax Therapeutics (Tenax Therapeutics) Headlines

From GuruFocus

Tenax Therapeutics Provides 2023 Business Update

By sperokesalga sperokesalga 04-12-2023

Tenax Therapeutics, Inc. Expands Board of Directors

By Business Wire Business Wire 03-02-2021